Citations

Clear

9 citation(s) found for "Stavropoulos, G".

Computer‐aided detection for esophageal achalasia (with video)
Shiwaku, Hironari , Misawa, Masashi , Inoue, Haruhiro , Boškoski, Ivo , Shimamura, Yuto , Ikebuchi, Yuichiro , Ominami, Masaki , Htet, Hein , Messmann, H, Colosso, Bianca Maria Quarta , Repici, Alessandro , Stavropoulos, Stavros N. , Bechara, Robert , Sethi, Amrita, Beyna, Torsten , Santi, Esperanza Grace , Sharma, Prateek , Eleftheriadis, Nikolas, Minami, Hitomi, Haber, Gregory , Seewald, Stefan , Shiwaku, Akio, Shiwaku, Yoshiyuki, Mori, Kensaku, Costamagna, Guido , Shimamura, Yuto , Ikebuchi, Yuichiro , Iwaya, Yugo , Htet, Hein Myat Thu , Colosso, Bianca Maria Quarta , Bechara, Robert , Kahaleh, Michel , Beyna, Torsten , Jiang, Kai, Oda, Masahiro , Familiari, Pietro , Hayee, Bu , Ho, Khek Yu , So, Jimmy Bok Yan , Bhandari, Pradeep , Grimes, Kevin L. , Maselli, Roberta , Hassan, Cesare , Fukami, Norio , Kahaleh, Michel , Sethi, Amrita , Neuhaus, Horst Ekkehard , Chiu, Philip Wai Yan , Eleftheriadis, Nikolas, Draganov, Peter V. , Mori, Kensaku , Kudo, Shin‐ei , Hasegawa, Suguru

Mayo Clinic

Digestive Endoscopy | June 12, 2025 | Volume: 37 | Issue: 8 | Pages: 851-861

10.1111/den.15028 | PMID 40506418 Get It

ObjectivesAchalasia is an esophageal motility disorder that impairs quality of life and is often missed (20–50%) on endoscopy. A newly developed computer‐aided detection (CAD) software has shown high accuracy for achalasia diagnosis in preclinical settings. However, its benefit in a clinical setting remains unclear.MethodsBetween February and August 2023, 83 endoscopists from 27 centers assessed 50 randomized endoscopic videos (25 achalasia, 25 nonachalasia) without and with CAD. Endoscopists assessed videos without CAD, then with CAD after 2 months. The primary end‐point was improvement in sensitivity for nonexperienced endoscopists (no endoscopic experience of achalasia). Sensitivity, specificity, and accuracy with and without CAD were compared using the McNemar test.ResultsSensitivity for diagnosing achalasia increased significantly with CAD, rising from 74.2% (95% confidence interval [CI] 72.2–76.0%) to 91.2% (95% CI 89.9–92.4%) for all readers, showing a difference of 17.1% (95% CI 15.1–19.0%). Specifically, sensitivity improved from 66.9% (95% CI 63.6–70.0%) to 91.9% (95% CI 89.9–93.6%) among nonexperienced endoscopists, resulting in a difference of 25.0% (95% CI 21.7–28.4%), and from 79.5% (95% CI 77.1–81.8%) to 90.8% (95% CI 89.0–92.3%) among experienced endoscopists (endoscopic experience of at least one achalasia case), with a difference of 11.3% (95% CI 8.9–13.6%). Accuracy and specificity improved significantly with CAD assistance, regardless of reader's experience.ConclusionCAD improves achalasia detection by 17%, confirming preclinical results. The benefit was higher for nonexperienced endoscopists. CAD assistance may lead to prompt and effective treatment, minimizing the risk of false‐negative diagnosis in clinical practice.Trial registrationThis study was registered in the University Hospital Medical Information Network Clinical Trial Registry (https://www.umin.ac.jp/ctr/) number: UMIN000053047.
Major clinical outcomes in patients with symptomatic versus asymptomatic atrial fibrillation: a Bayesian and frequentist meta-analysis
Siontis, Konstantinos C. , Stavropoulos, George, Giannakoulas, George , Katritsis, Demosthenes G. , Karakasis, Paschalis , Pamporis, Konstantinos , Theofilis, Panagiotis , Samaras, Athanasios , Patoulias, Dimitrios , Stachteas, Panagiotis , Karagiannidis, Efstratios , Stavropoulos, G, Tzikas, Apostolos , Kassimis, George , Karamitsos, Theodoros D. , Fragakis, Nikolaos

Mayo Clinic

Europace | May 23, 2025 | Volume: 27 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euaf085.295 Get It

Abstract Background Although a rhythm control strategy is associated with an overall better prognosis in atrial fibrillation (AF), current guidelines suggest that only highly selected asymptomatic patients may be considered candidates for AF catheter ablation. Therefore, this study aimed to evaluate the association between symptom status and clinical outcomes in patients with AF. Methods A comprehensive search of Medline, the Cochrane Library, and Scopus was conducted up until September 30, 2024. Study selection, data extraction, and quality assessment were performed independently by three reviewers. Random-effects meta-analyses were used to pool the evidence. Results A total of 36 studies, comprising 217,850 participants, were included. Frequentist analysis revealed no significant difference between symptomatic and asymptomatic AF patients in terms of all-cause mortality [hazard ratio (HR) = 0.97, 95% confidence interval (CI)= (0.80, 1.17)], cardiovascular mortality (HR= 1.04, 95% CI= [0.72, 1.49]), thromboembolism (HR= 1.06, 95% CI= [0.87, 1.28]), stroke (HR= 1.06, 95% CI= [0.84, 1.34]), hospitalization (HR= 1.34, 95% CI= [0.89, 2.02]), and myocardial infarction (HR= 0.98, 95% CI= [0.70, 1.36]). However, symptomatic patients exhibited a 33% increased risk of new-onset heart failure (HR= 1.33, 95% CI= [1.19, 1.49]) and a 30% reduced risk of progression to permanent AF (HR= 0.70, 95% CI= [0.54, 0.89]). Bayesian analysis produced similar results, although the association between symptom status and new-onset heart failure was not statistically significant [HR = 1.27, 95% credible interval (CrI)= (0.76, 1.93); Bayes factor (BF10)= 1.2]. Symptomatic patients had higher odds of receiving antiarrhythmic drugs (odds ratio [OR]= 1.64, 95% CI= [1.33, 2.03]) and ablation therapy (OR= 1.47, 95% CI= [1.06, 2.05]) compared to their asymptomatic counterparts. Conclusions The risk of major clinical outcomes does not significantly differ between AF patients with and without symptoms. However, asymptomatic patients have a higher risk of progressing to permanent AF.
Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis
Karakasis, Paschalis , Pamporis, Konstantinos, Siontis, Konstantinos C. , Samaras, Athanasios , Karagiannidis, Efstratios , Stavropoulos, George, Tzikas, Apostolos , Katritsis, Demosthenes G. , Theofilis, Panagiotis , Samaras, Athanasios , Patoulias, Dimitrios , Karagiannidis, Efstratios , Tzikas, Apostolos , Kassimis, George , Giannakoulas, George , Fragakis, Nikolaos , Karakasis, Paschalis , Pamporis, Konstantinos , Stachteas, Panagiotis , Stavropoulos, George, Karamitsos, Theodoros D.

Mayo Clinic

European Heart Journal | September 27, 2024 | Volume: 46 | Issue: 13 | Pages: 1189-1202

10.1093/eurheartj/ehae694 | PMID 39428997 Get It

Abstract Background and Aims Current guidelines suggest that asymptomatic atrial fibrillation (AF) is independently associated with increased risks of stroke and mortality compared with symptomatic AF. Considering that recent investigations have provided conflicting results, the present study aimed to evaluate the association between symptom status and clinical outcomes in patients with AF. Methods Medline, Cochrane Library, and Scopus were searched until 25 March 2024. Triple-independent study selection, data extraction and quality assessment were performed. Evidence was pooled using random-effects meta-analyses. Results Thirty-six studies (217 850 participants) were included. Based on the frequentist analysis, symptomatic individuals had no significant difference in the risk of all-cause mortality [hazard ratio (HR) .97, 95% confidence interval (CI) .80–1.17], cardiovascular mortality (HR 1.04, 95% CI .72–1.49), thromboembolism (HR 1.06, 95% CI .87–1.28), stroke (HR 1.06, 95% CI .84–1.34), hospitalization (HR 1.34, 95% CI .89–2.02), and myocardial infarction (HR .98, 95% CI .70–1.36), compared to the asymptomatic group. Symptomatic patients had a 33% increased risk of new-onset heart failure (HR 1.33, 95% CI 1.19–1.49) and a 30% lower risk of progression to permanent AF (HR .70, 95% CI .54–.89). The Bayesian analysis yielded comparable results, yet the association between symptom status and new-onset heart failure was not significant (HR 1.27, 95% credible interval .76–1.93; Bayes factor = 1.2). Symptomatic patients had higher odds of receiving antiarrhythmic drugs (odds ratio [OR] 1.64, 95% CI 1.33–2.03) and ablation therapy (OR 1.47, 95% CI 1.06–2.05) compared to asymptomatic cases. Conclusions The risk of major clinical outcomes did not differ between individuals with and without AF-related symptoms. Asymptomatic patients had a greater hazard of progression to permanent AF.
S1006 Initial Multicenter Experience Using a Novel Endoscopic Tack and Suture System for Challenging Gastrointestinal Defect Closure and Stent Fixation
Mahmoud, Tala , Song, Louis Wong Kee, Alansari, Tarek H., Stavropoulos, Stavros N. , Ramberan, Hemchand, Marya, Neil B. , Rau, Prashanth , Marshall, Christopher , Bejjani, Michael , Khashab, Mouen A. , Haber, Gregory, Aihara, Hiroyuki , Antillon-Galdamez, Mainor R., Fukami, Norio , Marya, Neil B. , Ghandour, Bachir , Chandrasekhara, Vinay , Dayyeh, Barham K. Abu , Storm, Andrew C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S479-S480

10.14309/01.ajg.0000777556.78873.3f Get It

Deep Learning Based on MRI for Differentiation of Low‐ and High‐Grade in Low‐Stage Renal Cell Carcinoma
Chang, Marcello , Wang, Robin , Xi, I., Huang, Raymond Y. , Vallières, Martin , Habibollahi, Peiman , Dagli, Mandeep , Zhang, Paul J. , Silva, Alvin C. , Yang, Li , Zhang, Zishu , Bai, Harrison X. , Stavropoulos, S. William, Bai, Harrison X. , Bai, Harrison X , Huang, Raymond , Zhao, Yijun , Chang, Ken , Palmer, Matthew R. , Soulen, Michael C

Mayo Clinic

Journal of Magnetic Resonance Imaging | March 28, 2020 | Volume: 52 | Issue: 5 | Pages: 1542-1549

10.1002/jmri.27153 | PMID 32222054 Get It

BackgroundPretreatment determination of renal cell carcinoma aggressiveness may help to guide clinical decision‐making.PurposeTo evaluate the efficacy of residual convolutional neural network using routine MRI in differentiating low‐grade (grade I–II) from high‐grade (grade III–IV) in stage I and II renal cell carcinoma.Study TypeRetrospective.PopulationIn all, 376 patients with 430 renal cell carcinoma lesions from 2008–2019 in a multicenter cohort were acquired. The 353 Fuhrman‐graded renal cell carcinomas were divided into a training, validation, and test set with a 7:2:1 split. The 77 WHO/ISUP graded renal cell carcinomas were used as a separate WHO/ISUP test set.Field Strength/Sequence1.5T and 3.0T/T2‐weighted and T1 contrast‐enhanced sequences.AssessmentThe accuracy, sensitivity, and specificity of the final model were assessed. The receiver operating characteristic (ROC) curve and precision‐recall curve were plotted to measure the performance of the binary classifier. A confusion matrix was drawn to show the true positive, true negative, false positive, and false negative of the model.Statistical TestsMann–Whitney U‐test for continuous data and the chi‐square test or Fisher's exact test for categorical data were used to compare the difference of clinicopathologic characteristics between the low‐ and high‐grade groups. The adjusted Wald method was used to calculate the 95% confidence interval (CI) of accuracy, sensitivity, and specificity.ResultsThe final deep‐learning model achieved a test accuracy of 0.88 (95% CI: 0.73–0.96), sensitivity of 0.89 (95% CI: 0.74–0.96), and specificity of 0.88 (95% CI: 0.73–0.96) in the Fuhrman test set and a test accuracy of 0.83 (95% CI: 0.73–0.90), sensitivity of 0.92 (95% CI: 0.84–0.97), and specificity of 0.78 (95% CI: 0.68–0.86) in the WHO/ISUP test set.Data ConclusionDeep learning can noninvasively predict the histological grade of stage I and II renal cell carcinoma using conventional MRI in a multiinstitutional dataset with high accuracy.Level of Evidence3Technical Efficacy Stage2
Deep Learning to Distinguish Benign from Malignant Renal Lesions Based on Routine MR Imaging
Xi, I., Wang, Robin , Chang, Marcello , Purkayastha, Subhanik , Chang, Ken, Huang, Raymond Y. , Silva, Alvin C. , Vallières, Martin , Habibollahi, Peiman , Zou, Beiji , Zhang, Paul J. , Zhang, Zishu , Bai, Harrison X. , Stavropoulos, S. William, Chang, Marcello , Vallières, Martin , Fan, Yong , Gade, Terence P , Soulen, Michael C , Huang, Raymond , Zhao, Yijun

Mayo Clinic

Clinical Cancer Research | January 14, 2020 | Volume: 26 | Issue: 8 | Pages: 1944-1952

10.1158/1078-0432.ccr-19-0374 | PMID 31937619 Get It

Abstract Purpose: With increasing incidence of renal mass, it is important to make a pretreatment differentiation between benign renal mass and malignant tumor. We aimed to develop a deep learning model that distinguishes benign renal tumors from renal cell carcinoma (RCC) by applying a residual convolutional neural network (ResNet) on routine MR imaging. Experimental Design: Preoperative MR images (T2-weighted and T1-postcontrast sequences) of 1,162 renal lesions definitely diagnosed on pathology or imaging in a multicenter cohort were divided into training, validation, and test sets (70:20:10 split). An ensemble model based on ResNet was built combining clinical variables and T1C and T2WI MR images using a bagging classifier to predict renal tumor pathology. Final model performance was compared with expert interpretation and the most optimized radiomics model. Results: Among the 1,162 renal lesions, 655 were malignant and 507 were benign. Compared with a baseline zero rule algorithm, the ensemble deep learning model had a statistically significant higher test accuracy (0.70 vs. 0.56, P = 0.004). Compared with all experts averaged, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.60, P = 0.053), sensitivity (0.92 vs. 0.80, P = 0.017), and specificity (0.41 vs. 0.35, P = 0.450). Compared with the radiomics model, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.62, P = 0.081), sensitivity (0.92 vs. 0.79, P = 0.012), and specificity (0.41 vs. 0.39, P = 0.770). Conclusions: Deep learning can noninvasively distinguish benign renal tumors from RCC using conventional MR imaging in a multi-institutional dataset with good accuracy, sensitivity, and specificity comparable with experts and radiomics.
Clinical delineation of the PACS1‐related syndrome—Report on 19 patients
Schuurs-Hoeijmakers, Janneke , Landsverk, Megan , Foulds, Nicola , Kukolich, Mary K. , Gavrilova, Ralitza H. , Greville‐Heygate, Stephanie , Hanson‐Kahn, Andrea , Bernstein, Jonathan A. , Glass, Jennifer, Burrow, Thomas Andrew, Husami, Ammar , Collins, Kathleen , Wusik, Katie, Aa, Nathalie Van der, Kooy, R. Frank , Brown, Kate Tatton, Gadzicki, Dorothea, Kini, Usha , McGehee, Frank T., Selby, Katherine, Tarailo‐Graovac, Maja , Allen, Margot Van, Stavropoulos, Dimitri J. , Marshall, Christian R. , Merico, Daniele , Gregor, Anne , Zweier, Christiane , Chu, Yoyo W. Y., Vries, Bert B.A. de , Brunner, Han G. , study, DDD, Chitayat, David A. , Collins, Kathleen , Álvarez, Sara , Fernández‐Jaén, Alberto , Allen, Margot I. Van, Karnebeek, Clara van , Hopkin, Robert J. , Chung, Hon-Yin B , Devriendt, Koenraad , Hurles, Matthew E. , study, DDD, Kooy, Frank , de Vries, Bert B A , Marshall, Christian R.

Mayo Clinic

American Journal of Medical Genetics Part A | February 4, 2016 | Volume: 170 | Issue: 3 | Pages: 670-675

10.1002/ajmg.a.37476 | PMID 26842493 Get It

We report on 19 individuals with a recurrent de novo c.607C>T mutation in PACS1. This specific mutation gives rise to a recognizable intellectual disability syndrome. There is a distinctive facial appearance (19/19), characterized by full and arched eyebrows, hypertelorism with downslanting palpebral fissures, long eye lashes, ptosis, low set and simple ears, bulbous nasal tip, wide mouth with downturned corners and a thin upper lip with an unusual “wavy” profile, flat philtrum, and diastema of the teeth. Intellectual disability, ranging from mild to moderate, was present in all. Hypotonia is common in infancy (8/19). Seizures are frequent (12/19) and respond well to anticonvulsive medication. Structural malformations are common, including heart (10/19), brain (12/16), eye (10/19), kidney (3/19), and cryptorchidism (6/12 males). Feeding dysfunction is presenting in infancy with failure to thrive (5/19), gastroesophageal reflux (6/19), and gastrostomy tube placement (4/19). There is persistence of oral motor dysfunction. We provide suggestions for clinical work‐up and management and hope that the present study will facilitate clinical recognition of further cases. © 2016 Wiley Periodicals, Inc.
Deletions in 16q24.2 are associated with autism spectrum disorder, intellectual disability and congenital renal malformation
Handrigan, Gregory R., Lionel, Anath C. , Pinsk, Maury , Vaags, Andrea K., Marshall, Christian R. , Dyack, Sarah , Fernandez, Bridget A. , Stegman, Joseph C., Shaffer, Lisa G. , Goodenberger, McKinsey L. , Hodge, Jennelle C. , Cain, Jason E. , Babul‐Hirji, Riyana, Stavropoulos, Dimitri J. , Yiu, Verna, Scherer, Stephen W. , Rosenblum, Norman D. , Chitayat, David A. , Escobar, Luis Fernando , Rosenfeld, Jill A. , Scherer, Stephen W , Goodenberger, McKinsey , Marshall, Christian R.

Mayo Clinic

Journal of Medical Genetics | January 18, 2013 | Volume: 50 | Issue: 3 | Pages: 163-173

10.1136/jmedgenet-2012-101288 | PMID 23335808 Get It

Background The contribution of copy-number variation (CNV) to disease has been highlighted with the widespread adoption of array-based comparative genomic hybridisation (aCGH) and microarray technology. Contiguous gene deletions involving ANKRD11 in 16q24.3 are associated with autism spectrum disorder (ASD) and intellectual disability (ID), while 16q24.1 deletions affecting FOXF1 are associated with congenital renal malformations, alveolar capillary dysplasia, and various other abnormalities. The disease associations of deletions in the intervening region, 16q24.2, have only been defined to a limited extent. Aim To determine whether deletions affecting 16q24.2 are correlated with congenital anomalies. Methods 35 individuals, each having a deletion in 16q24.2, were characterised clinically and by aCGH and/or SNP-genotyping microarray. Results Several of the 35 16q24.2 deletions identified here closely abut or overlap the coding regions of FOXF1 and ANKRD11, two genes that have been previously associated with the disease. 25 patients were reported to have ASD/ID, and three were found to have bilateral hydronephrosis. 14 of the deletions associated with ASD/ID overlap the coding regions of FBXO31 and MAP1LC3B. These same genes and two others, C16orf95 and ZCCHC14, are also included in the area of minimal overlap of the three deletions associated with hydronephrosis. Conclusions Our data highlight 16q24.2 as a region of interest for ASD, ID and congenital renal malformations. These conditions are associated, albeit without complete penetrance, with deletions affecting C16orf95, ZCCHC14, MAP1LC3B and FBXO31. The function of each gene in development and disease warrants further investigation.